Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Recombinant erythropoietin acutely decreases renal perfusion and decouples the renin-angiotensin-aldosterone system.

Aachmann-Andersen NJ, Christensen SJ, Lisbjerg K, Oturai P, Johansson PI, Holstein-Rathlou NH, Olsen NV.

Physiol Rep. 2018 Mar;6(5). doi: 10.14814/phy2.13573.

2.

Intra-dialytic hypertension is associated with high mortality in hemodialysis patients.

Choi CY, Park JS, Yoon KT, Gil HW, Lee EY, Hong SY.

PLoS One. 2017 Jul 25;12(7):e0181060. doi: 10.1371/journal.pone.0181060. eCollection 2017.

3.

Regeneration in the nervous system with erythropoietin.

Maiese K.

Front Biosci (Landmark Ed). 2016 Jan;21(3):561-596.

4.

Erythropoietin and diabetes mellitus.

Maiese K.

World J Diabetes. 2015 Oct 25;6(14):1259-73. doi: 10.4239/wjd.v6.i14.1259. Review.

5.

Plasma F2-isoprostane class VI isomers at 12-18 weeks of pregnancy are associated with later occurrence of preeclampsia.

Bilodeau JF, Qin Wei S, Larose J, Greffard K, Moisan V, Audibert F, Fraser WD, Julien P.

Free Radic Biol Med. 2015 Aug;85:282-7. doi: 10.1016/j.freeradbiomed.2015.05.012. Epub 2015 May 19.

6.

Hypertension Treatment for Patients with Advanced Chronic Kidney Disease.

Sinha AD, Agarwal R.

Curr Cardiovasc Risk Rep. 2014 Oct;8(10). pii: 400.

7.

Assessment and management of hypertension in patients on dialysis.

Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR.

J Am Soc Nephrol. 2014 Aug;25(8):1630-46. doi: 10.1681/ASN.2013060601. Epub 2014 Apr 3. Review.

8.

Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease.

Briet M, Barhoumi T, Mian MO, Sierra C, Boutouyrie P, Davidman M, Bercovitch D, Nessim SJ, Frisch G, Paradis P, Lipman ML, Schiffrin EL.

J Am Heart Assoc. 2013 Apr 12;2(2):e000128. doi: 10.1161/JAHA.113.000128.

9.

Epidemiology of interdialytic ambulatory hypertension and the role of volume excess.

Agarwal R.

Am J Nephrol. 2011;34(4):381-90. doi: 10.1159/000331067. Epub 2011 Sep 2.

10.

Cardiovascular effects of erythropoietin an update.

Santhanam AV, d'Uscio LV, Katusic ZS.

Adv Pharmacol. 2010;60:257-85. doi: 10.1016/B978-0-12-385061-4.00009-X. Review.

11.

Effects of recombinant human erythropoietin in normal humans.

Lundby C, Olsen NV.

J Physiol. 2011 Mar 15;589(Pt 6):1265-71. doi: 10.1113/jphysiol.2010.195917. Epub 2010 Aug 31. Review.

12.

Erythropoietin down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humans.

Olsen NV, Aachmann-Andersen NJ, Oturai P, Munch-Andersen T, Bornø A, Hulston C, Holstein-Rathlou NH, Robach P, Lundby C.

J Physiol. 2011 Mar 15;589(Pt 6):1273-81. doi: 10.1113/jphysiol.2010.194241. Epub 2010 Aug 19.

13.

Hypertension in dialysis and kidney transplant patients.

Prasad GV, Ruzicka M, Burns KD, Tobe SW, Lebel M.

Can J Cardiol. 2009 May;25(5):309-14. Review.

14.

Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits.

Noguchi K, Yamashiro S, Matsuzaki T, Sakanashi M, Nakasone J, Miyagi K, Sakanashi M.

Br J Pharmacol. 2001 Jun;133(3):395-405.

Supplemental Content

Support Center